Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.
about
Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragmentsSafety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial ProgramIsolation and characterization of anti c-met single chain fragment variable (scFv) antibodies.Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis.Incomplete target neutralization by the anti-cancer antibody rilotumumab.Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growthTargeting the oncogenic Met receptor by antibodies and gene therapy.The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo.HGF-MET cascade, a key target for inhibiting cancer metastasis: the impact of NK4 discovery on cancer biology and therapeutics.Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody.Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain.Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist.Tumour growth stimulation following partial hepatectomy in mice is associated with increased upregulation of c-Met.Novel strategy for a bispecific antibody: induction of dual target internalization and degradation.Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy.Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
P2860
Q34459696-E10B5714-770C-4007-933D-8C701C329887Q36133180-8B64A973-9627-4665-BDF0-DAF392D9747EQ36250366-90BFAEAE-6EDE-44F2-94F7-25CE2E35D6F4Q36411841-0CF1A490-96AE-46E6-9EE8-5DC26A148B0CQ36757173-46B45D2C-83CE-45A8-874D-BD68AAE22186Q37138513-E7181DE2-8217-45EE-B8BC-38007F1960ECQ37138521-7E61ACB4-D10D-45C6-A2F0-E7E5813E7A70Q38216590-FFD29E48-1257-4FEA-B44E-396210EC3AAFQ38239580-949DC11A-5C12-4378-AEF0-8F5EC079BBF6Q38912207-CD9AF536-15F1-4CEA-B6F7-14A61D28ADE3Q39002694-AE53E415-F6EB-4384-8935-19E9144E6F96Q39214964-86BD39E7-48C3-4ACA-865A-977423A1572AQ39233148-A4D79C03-8550-4305-82E0-2F73A4EB0BC6Q41490164-4527C594-04CD-498D-90D1-06D54AA62D37Q41660598-02A626A1-3ED5-43B2-A5D0-45555B299783Q42088207-DD96E1E3-F031-4597-8CFB-D7A17C066A99Q44408938-86682249-71D3-46C6-93B2-11E25B20D32CQ50882714-17B54744-4291-4393-892D-1F5FE017AB9DQ53789447-77A452CA-175E-4C97-B67B-21DE4A6BA6F8Q58724935-05A13E26-F0E1-458C-9785-A2D6FA1B927A
P2860
Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Non-agonistic bivalent antibod ...... cific for tumor related c-MET.
@ast
Non-agonistic bivalent antibod ...... cific for tumor related c-MET.
@en
Non-agonistic bivalent antibod ...... cific for tumor related c-MET.
@nl
type
label
Non-agonistic bivalent antibod ...... cific for tumor related c-MET.
@ast
Non-agonistic bivalent antibod ...... cific for tumor related c-MET.
@en
Non-agonistic bivalent antibod ...... cific for tumor related c-MET.
@nl
prefLabel
Non-agonistic bivalent antibod ...... cific for tumor related c-MET.
@ast
Non-agonistic bivalent antibod ...... cific for tumor related c-MET.
@en
Non-agonistic bivalent antibod ...... cific for tumor related c-MET.
@nl
P2093
P2860
P50
P1433
P1476
Non-agonistic bivalent antibod ...... cific for tumor related c-MET.
@en
P2093
Angela A Vitali
Ermanno Gherardi
Luisa Iamele
Roger Murphy
Zhanqi Liu
P2860
P304
P356
10.1371/JOURNAL.PONE.0034658
P407
P577
2012-04-12T00:00:00Z